Paul Phan

Paul Phan

Auto-generated profile, based on publicly available information

Paul Phan

Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MLMiles H. Linde
Miles H. Linde
AFAmy C. Fan
Amy C. Fan
TKThomas Köhnke
Thomas Köhnke
ATAaron C. Trotman-Grant
Aaron C. Trotman-Grant
SGSarah F. Gurev
Sarah F. Gurev
RMRavindra Majeti
Ravindra Majeti
Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAA) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid-lineage reprogramming to directly convert cancer cells into tumor-reprogrammed antigen-presenting cells (TR-APC). Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. Finally, we demonstrate the clinical applicability of this approach by generating TR-APCs from primary clinical specimens and stimulating autologous patient-derived T cells. Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology. Significance: Despite recent advances, the clinical benefit provided by cancer vaccination remains limited. We present a cancer vaccination approach leveraging myeloid-lineage reprogramming of cancer cells into APCs, which subsequently activate anticancer immunity through presentation of self-derived cancer antigens. Both hematologic and solid malignancies derive significant therapeutic benefit from reprogramming-based immunotherapy. This article is highlighted in the In This Issue feature, p. 1027

14 February 2024 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
TKThomas Köhnke
Thomas Köhnke
KNKevin A. Nuno
Kevin A. Nuno
CACatherine C. Alder
Catherine C. Alder
EGEric J. Gars
Eric J. Gars
PPPaul Phan
Paul Phan
RMRavindra Majeti
Ravindra Majeti
Mutations in additional sex combs like 1 (ASXL1) confer poor prognosis both in myeloid malignancies and in premalignant clonal hematopoiesis (CH). However, the mechanisms by which these mutations contribute to disease initiation remain unresolved, and mutation-specific targeting has remained elusive. To address this, we developed a human disease model that recapitulates the disease trajectory from ASXL1-mutant CH to lethal myeloid malignancy. We demonstrate that mutations in ASXL1 lead to the expression of a functional, truncated protein and determine that truncated ASXL1 leads to global redistribution of the repressive chromatin mark H2AK119Ub, increased transposase-accessible chromatin, and activation of both myeloid and stem cell gene-expression programs. Finally, we demonstrate that H2AK119Ub levels are tied to truncated ASXL1 expression levels and leverage this observation to demonstrate that inhibition of the PRC1 complex might be an ASXL1-mutant–specific therapeutic vulnerability in both premalignant CH and myeloid malignancy. Significance: Mutant ASXL1 is a common driver of CH and myeloid malignancy. Using primary human HSPCs, we determine that truncated ASXL1 leads to redistribution of H2AK119Ub and may affect therapeutic vulnerability to PRC1 inhibition.

16 September 2024
Verified
Other
Open access
PDF file
MLMiles H. Linde
Miles H. Linde
AFAmy C. Fan
Amy C. Fan
TKThomas Kohnke
Thomas Kohnke
ATAaron C. Trotman-Grant
Aaron C. Trotman-Grant
SGSarah F. Gurev
Sarah F. Gurev
RMRavindra Majeti
Ravindra Majeti
In vivo doxycycline administration results in significant TR-APC induction throughout tumors

16 September 2024
Verified
Other
Open access
PDF file
MLMiles H. Linde
Miles H. Linde
AFAmy C. Fan
Amy C. Fan
TKThomas Kohnke
Thomas Kohnke
ATAaron C. Trotman-Grant
Aaron C. Trotman-Grant
SGSarah F. Gurev
Sarah F. Gurev
RMRavindra Majeti
Ravindra Majeti
In vivo TR-APC induction drives oligoclonal T cell expansion

16 September 2024
Verified
Other
Open access
PDF file
MLMiles H. Linde
Miles H. Linde
AFAmy C. Fan
Amy C. Fan
TKThomas Kohnke
Thomas Kohnke
ATAaron C. Trotman-Grant
Aaron C. Trotman-Grant
SGSarah F. Gurev
Sarah F. Gurev
RMRavindra Majeti
Ravindra Majeti
In vivo TR-APC induction results in expansion of activated and memory T cells, and decreased frequency of Tregs

11 December 2025
Verified
Other
Open access
MLMiles H. Linde
Miles H. Linde
AFAmy C. Fan
Amy C. Fan
TKThomas Köhnke
Thomas Köhnke
ATAaron C. Trotman-Grant
Aaron C. Trotman-Grant
SGSarah F. Gurev
Sarah F. Gurev
RMRavindra Majeti
Ravindra Majeti
In vivo doxycycline administration results in significant TR-APC induction throughout tumors